OBJECTIVES: Sirolimus has been used in pediatric cardiac transplantation for the past decade for chronic renal dysfunction, recurrent rejection, and/or coronary allograft vasculopathy. There has been concern regarding the effect of sirolimus on wound healing and other postoperative complications. To date, the pediatric literature on its use is limited and has not specifically addressed its use in the perioperative period following repeat cardiac transplantation. METHODS: We compared the patients in our institution who received sirolimus before repeat cardiac transplantation to those in the same era who did not receive sirolimus. RESULTS: Of the 5 patients in the study group, 5 (100%) developed pleural effusions vs 1 (17%) in the control group (p=0.013). There was no increase in mortality in the sirolimus group, and there were no significant differences in renal dysfunction, serious bacterial infection, rejection, or postoperative length of stay. CONCLUSIONS: In this small data set, there was a statistically significant increase in pleural effusions in patients on sirolimus. Further study is needed to develop an appropriate strategy to avoid postoperative complications in this patient population.
OBJECTIVES:Sirolimus has been used in pediatric cardiac transplantation for the past decade for chronic renal dysfunction, recurrent rejection, and/or coronary allograft vasculopathy. There has been concern regarding the effect of sirolimus on wound healing and other postoperative complications. To date, the pediatric literature on its use is limited and has not specifically addressed its use in the perioperative period following repeat cardiac transplantation. METHODS: We compared the patients in our institution who received sirolimus before repeat cardiac transplantation to those in the same era who did not receive sirolimus. RESULTS: Of the 5 patients in the study group, 5 (100%) developed pleural effusions vs 1 (17%) in the control group (p=0.013). There was no increase in mortality in the sirolimus group, and there were no significant differences in renal dysfunction, serious bacterial infection, rejection, or postoperative length of stay. CONCLUSIONS: In this small data set, there was a statistically significant increase in pleural effusions in patients on sirolimus. Further study is needed to develop an appropriate strategy to avoid postoperative complications in this patient population.
Authors: Christian Benden; Paul Aurora; Leah B Edwards; Anna Y Kucheryavaya; Jason D Christie; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2011-10 Impact factor: 10.247
Authors: Ian C Balfour; Sopheak W Srun; Ellen G Wood; Craig W Belsha; Donna L Marshall; Barbara R Ferdman Journal: J Heart Lung Transplant Date: 2006-05 Impact factor: 10.247
Authors: S Kuppahally; A Al-Khaldi; D Weisshaar; H A Valantine; P Oyer; R C Robbins; S A Hunt Journal: Am J Transplant Date: 2006-05 Impact factor: 8.086
Authors: Eugenia Raichlin; Jang-Ho Bae; Zain Khalpey; Brooks S Edwards; Walter K Kremers; Alfredo L Clavell; Richard J Rodeheffer; Robert P Frantz; Charanjit Rihal; Amir Lerman; Sudhir S Kushwaha Journal: Circulation Date: 2007-11-19 Impact factor: 29.690
Authors: A Akcan-Arikan; M Zappitelli; L L Loftis; K K Washburn; L S Jefferson; S L Goldstein Journal: Kidney Int Date: 2007-03-28 Impact factor: 10.612
Authors: Michael Zakliczynski; Jerzy Nozynski; Alfred Kocher; Maria K Lizak; Helena Zakliczynska; Roman Przybylski; Jacek Wojarski; Marian Zembala Journal: Wound Repair Regen Date: 2007 May-Jun Impact factor: 3.617